Jenburkt Pharmaceuticals Limited (BOM:524731)
India · Delayed Price · Currency is INR 1,025.50
-35.80 (-3.37%)
At close: Jan 23, 2026
Jenburkt Pharmaceuticals Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
Operating Revenue | 1,590 | 1,517 | 1,420 | 1,367 | 1,240 | 1,093 | Upgrade |
Other Revenue | - | - | 0 | - | - | - | Upgrade |
| 1,590 | 1,517 | 1,420 | 1,367 | 1,240 | 1,093 | Upgrade | |
Revenue Growth (YoY) | 7.27% | 6.85% | 3.82% | 10.30% | 13.44% | -8.07% | Upgrade |
Cost of Revenue | 311.36 | 308.3 | 313.42 | 338.6 | 321.51 | 307.65 | Upgrade |
Gross Profit | 1,279 | 1,209 | 1,106 | 1,029 | 918.3 | 785.29 | Upgrade |
Selling, General & Admin | 480.03 | 455.36 | 424.89 | 388.07 | 364.91 | 323.77 | Upgrade |
Other Operating Expenses | 381.26 | 349.14 | 350.1 | 336.35 | 280.04 | 263.08 | Upgrade |
Operating Expenses | 891.65 | 831.78 | 798.38 | 747.01 | 663.93 | 607.21 | Upgrade |
Operating Income | 387.23 | 376.84 | 307.87 | 281.88 | 254.37 | 178.09 | Upgrade |
Interest Expense | -3.66 | -3.8 | -2.3 | -3 | -3.48 | -4.24 | Upgrade |
Interest & Investment Income | 53.5 | 53.5 | 41.8 | 40.65 | 44.04 | 40.71 | Upgrade |
Currency Exchange Gain (Loss) | 4.93 | 4.93 | 3.32 | 7.6 | 2.45 | 2.22 | Upgrade |
Other Non Operating Income (Expenses) | 8.04 | -0.73 | -0.41 | 0.46 | -0.87 | -0.48 | Upgrade |
EBT Excluding Unusual Items | 450.04 | 430.74 | 350.28 | 327.59 | 296.51 | 216.29 | Upgrade |
Gain (Loss) on Sale of Investments | 8.58 | 8.58 | 1.33 | 0.04 | 0.02 | 0.06 | Upgrade |
Gain (Loss) on Sale of Assets | - | - | - | - | 1.84 | - | Upgrade |
Pretax Income | 458.63 | 439.33 | 351.76 | 328.65 | 298.71 | 216.42 | Upgrade |
Income Tax Expense | 128.63 | 118.72 | 91.99 | 82.58 | 75.74 | 51.39 | Upgrade |
Net Income | 329.99 | 320.61 | 259.77 | 246.07 | 222.97 | 165.02 | Upgrade |
Net Income to Common | 329.99 | 320.61 | 259.77 | 246.07 | 222.97 | 165.02 | Upgrade |
Net Income Growth | 8.90% | 23.42% | 5.57% | 10.36% | 35.12% | 10.98% | Upgrade |
Shares Outstanding (Basic) | 4 | 4 | 4 | 5 | 5 | 5 | Upgrade |
Shares Outstanding (Diluted) | 4 | 4 | 4 | 5 | 5 | 5 | Upgrade |
Shares Change (YoY) | 0.01% | - | -3.34% | -0.52% | - | - | Upgrade |
EPS (Basic) | 74.77 | 72.65 | 58.86 | 53.90 | 48.58 | 35.96 | Upgrade |
EPS (Diluted) | 74.77 | 72.65 | 58.86 | 53.90 | 48.58 | 35.96 | Upgrade |
EPS Growth | 8.89% | 23.42% | 9.21% | 10.93% | 35.12% | 10.98% | Upgrade |
Free Cash Flow | -16.79 | 81.92 | 55.7 | 149.48 | 62.17 | 183.1 | Upgrade |
Free Cash Flow Per Share | -3.81 | 18.56 | 12.62 | 32.74 | 13.55 | 39.90 | Upgrade |
Dividend Per Share | 18.000 | 18.000 | 15.300 | 14.400 | 12.000 | 10.200 | Upgrade |
Dividend Growth | 17.65% | 17.65% | 6.25% | 20.00% | 17.65% | 25.93% | Upgrade |
Gross Margin | 80.42% | 79.68% | 77.92% | 75.24% | 74.07% | 71.85% | Upgrade |
Operating Margin | 24.35% | 24.84% | 21.69% | 20.61% | 20.52% | 16.29% | Upgrade |
Profit Margin | 20.75% | 21.14% | 18.30% | 17.99% | 17.98% | 15.10% | Upgrade |
Free Cash Flow Margin | -1.06% | 5.40% | 3.92% | 10.93% | 5.01% | 16.75% | Upgrade |
EBITDA | 410.87 | 397.4 | 324.26 | 298.93 | 267.14 | 190.48 | Upgrade |
EBITDA Margin | 25.84% | 26.20% | 22.84% | 21.86% | 21.55% | 17.43% | Upgrade |
D&A For EBITDA | 23.64 | 20.56 | 16.4 | 17.05 | 12.77 | 12.4 | Upgrade |
EBIT | 387.23 | 376.84 | 307.87 | 281.88 | 254.37 | 178.09 | Upgrade |
EBIT Margin | 24.35% | 24.84% | 21.69% | 20.61% | 20.52% | 16.29% | Upgrade |
Effective Tax Rate | 28.05% | 27.02% | 26.15% | 25.13% | 25.36% | 23.75% | Upgrade |
Revenue as Reported | 1,666 | 1,584 | 1,466 | 1,419 | 1,289 | 1,136 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.